NEU-411 is being studied to see if it can slow PD progression in individuals with PD who have LRRK2 pathway overactivity (referred to as LRRK2-driven) based on their genetic profile.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Daniel Roque
Neurology-Movement Disorders
Clinical or Medical
Interventional
Brain, Head, Nervous System
Chronic Conditions
Movement
24-2748
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
